Search results
Results from the WOW.Com Content Network
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...
Leqembi's sales are projected to grow 13-fold to 56.5 billion yen ($361.28 million) in fiscal 2024 from the year ended in March, Eisai said in its annual results on Wednesday.
While Leqembi sales performed well outside the U.S. and Skyclarys The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the ...
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [ 2 ] [ 4 ] Lecanemab is an amyloid beta -directed antibody. [ 2 ] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [ 2 ]
Alzheimer’s drug Leqembi, the first medicine shown to slow the disease, has earned FDA approval. Learn more about the treatment and what this means for patients.
The British shipbuilding industry is a prime example of this with its industries suffering badly from the 1960s. In the early 1970s British yards still had the capacity to build all types and sizes of merchant ships but today they have been reduced to a small number specialising in defence contracts, luxury yachts and repair work.
Afrikaans; العربية; Azərbaycanca; বাংলা; 閩南語 / Bân-lâm-gú; Беларуская; Беларуская (тарашкевіца ...
That won't be enough to monitor patients who get on Leqembi, which reduces cognitive decline in mild to moderate Alzheimer's patients to avoid severe side effects, according to the company.